Cardiopatías Familiares y genética cardiovascular
Harvard Medical School
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Harvard Medical School (7)
2024
-
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993
-
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1821-1831
-
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy
Circulation: Heart Failure, Vol. 17, Núm. 7, pp. e011548
2015
-
Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain
Heart, Vol. 101, Núm. 13, pp. 1047-1053
2014
-
Merits and pitfalls of genetic testing in a hypertrophic cardiomyopathy clinic
Israel Medical Association Journal, Vol. 16, Núm. 11, pp. 707
2010
-
Novel missense mutations in exon 15 of desmoglein-2: Role of the intracellular cadherin segment in arrhythmogenic right ventricular cardiomyopathy?
Heart Rhythm, Vol. 7, Núm. 10, pp. 1446-1453
2005
-
Gene mutations in apical hypertrophic cardiomyopathy
Circulation, Vol. 112, Núm. 18, pp. 2805-2811